HiFiBiO Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, HiFiBiO Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
HiFiBiO Therapeutics: 4 sponsored US clinical trials, none currently recruiting.
HiFiBiO Therapeutics sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gastric Cancer, with 2 trials.
Upper-quartile sponsor footprint
HiFiBiO Therapeutics sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05789069
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05238883
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
NCT05229601
Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults
NCT04590430
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Therapeutic Areas
How the HiFiBiO Therapeutics early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 1 completed (25%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Gastric Cancer (2 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
HiFiBiO Therapeutics: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
HiFiBiO Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this HiFiBiO Therapeutics page
4 registered trials is a research-attention snapshot, not an endorsement of HiFiBiO Therapeutics or any single study.
- None of HiFiBiO Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Gastric Cancer is the condition HiFiBiO Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gastric Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. HiFiBiO Therapeutics pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.